Golden
Rani Therapeutics

Rani Therapeutics

A company developing biotherapeutics for the delivery of large drug molecules, peptides, proteins and antibodies

All edits

Edits on 18 Sep 2019
Golden AI
Golden AI edited on 18 Sep 2019 5:48 am
Edits made to:
Infobox (+1 properties)
Edits on 13 Sep 2019
Julius John Villarisco
Julius John Villarisco approved a suggestion from Golden's AI on 13 Sep 2019 7:48 pm
Edits made to:
Article (+15/-15 characters)

Article

On June 13, 2012 Rani Therapeutics completed their series A funding round with $4 million in funding from InCube VenturesInCube Ventures. 

Edits on 11 Sep 2019
Golden AI
Golden AI edited on 11 Sep 2019 3:53 am
Edits made to:
Infobox (+1 properties)
Edits on 12 Jun 2019
Golden AI
Golden AI edited on 12 Jun 2019 10:42 pm
Edits made to:
Infobox (+1 properties)
Edits on 30 Apr 2019
Jon Kirchman
Jon Kirchman approved a suggestion from Golden's AI on 30 Apr 2019 9:27 pm
Edits made to:
Article (+13/-13 characters)

Article

On May 26, 2015 Rani Therapeutics completed their series C funding round with $37.5 million in funding from Western Life Sciences Venture Fund, VentureHealthVentureHealth, The Stevanato Group, Pinemount Investment, Pacific Venture Opportunity Fund, Novartis, InCube Ventures, Google Ventures, and Crystal Horizon Investments. 

Edits on 25 Apr 2019
Golden AI
Golden AI edited on 25 Apr 2019 12:52 am
Edits made to:
Infobox (+1 properties)

Infobox

Industry
Edits on 30 Mar 2019
Sarah Rioflorido
Sarah Rioflorido approved a suggestion from Golden's AI on 30 Mar 2019 12:30 pm
Edits made to:
Article (+5/-5 characters)

Article

On February 7, 2018 Rani Therapeutics completed a venture funding round with $53 million in funding from ShireShire (lead investor), GeneScience Pharmaceuticals (lead investor), Cathey Venture (lead investor), Bossa Ventures (lead investor), Virtus Inspire Ventures, Ping An Ventures, Google Ventures, and AstraZeneca. 

Edits on 29 Mar 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 29 Mar 2019 3:33 pm
Edits made to:
Article (+19/-19 characters)

Article

  • Parathyroid HormoneParathyroid Hormone (PTH) - commonly used for the treatment of osteoporosis, PTH increases the concentration of calcium in the blood by acting upon the parathyroid hormone 1 & 2 receptor.
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 29 Mar 2019 1:15 pm
Edits made to:
Article (+11/-11 characters)

Article

On September 9, 2017 Rani Therapeutics completed their series D funding round with $39 million in funding from Google Ventures (lead investor), Novartis, and AstraZenecaAstraZeneca. 

Dawson Sewell
Dawson Sewell edited on 29 Mar 2019 12:27 pm
Edits made to:
Infobox (+5 properties)
Timeline (+6 events) (+1337 characters)
Article (+1556/-367 characters)
People (+9 characters)
Further reading (+3 rows) (+12 cells) (+699 characters)
Categories (+1/-2 topics)
Related Topics (+1 topics)

Article

Rani Therapeutics is biotherapeutics company based in San Jose, California and was founded in 2012 by Mir Imran. It develops novel approaches for the oral delivery of peptides, proteins, and therapeutic antibodies that can normally only be delivered through injections. The approach and technology for Rani Therapeutics was developed at InCube Labs, a multidisciplinary R&D lab focused on developing medical innovations.

Products

RanPill

It's main product, Rani's 'robotic' pill is a device which navigates through the stomach and enters the small intestine. The capsule then goes through a transformation and aligns itself and injects the drug into the intestinal wall.



Rani has identified several potential molecules to be used with the RaniPill:

...

It's main product, Rani's 'robotic' pill is a device which navigates through the stomach and enters the small intestine. The capsule then goes through a transformation and aligns itself and injects the drug into the intestinal wall. Rani has identified several potential molecules to be used with the RaniPill:

  • Parathyroid Hormone (PTH) - commonly used for the treatment of osteoporosis, PTH increases the concentration of calcium in the blood by acting upon the parathyroid hormoneparathyroid hormone 1 & 2 receptor.
  • TNF-alpha (TNFa) Inhibitors - supressessuppresses response to tumor necrosis factor, part of the inflammatory response. Used to treat a number of inflammatory disorders including rheumatoid arthritis and Crohn's disease.
  • Interleukin Antibodies - various antibodies targeting specific interleukins for the treatment of various inflammatory diseases, such as rheumatoid arthritisrheumatoid arthritis, Chrohn's disease, and psoriasispsoriasis.
  • PCSK9 - a treatment for cardiovascular disease that is often used with other therapies like statins to lower low-density lipoprotein cholesterol (LDL-C) for patients with hyperlipidemia.
  • Factor VIII, Factor IX, Factor X - treatments of blood clotting disorders, including Hemophilia A and B.

Funding

Series A

On June 13, 2012 Rani Therapeutics completed their series A funding round with $4 million in funding from InCube Ventures. 

Series B

On July 28, 2013 Rani Therapeutics completed their series B funding round with $9.4 million in funding from Google Ventures (lead investor) and InCube Ventures. 

Series C

On May 26, 2015 Rani Therapeutics completed their series C funding round with $37.5 million in funding from Western Life Sciences Venture Fund, VentureHealth, The Stevanato Group, Pinemount Investment, Pacific Venture Opportunity Fund, Novartis, InCube Ventures, Google Ventures, and Crystal Horizon Investments. 

Series D

On September 9, 2017 Rani Therapeutics completed their series D funding round with $39 million in funding from Google Ventures (lead investor), Novartis, and AstraZeneca. 

Venture

On February 7, 2018 Rani Therapeutics completed a venture funding round with $53 million in funding from Shire (lead investor), GeneScience Pharmaceuticals (lead investor), Cathey Venture (lead investor), Bossa Ventures (lead investor), Virtus Inspire Ventures, Ping An Ventures, Google Ventures, and AstraZeneca. 

People

Name
Role
Related Golden topics

Mir Imran

Founder, Chairman & CEO



Further reading

Title
Author
Link
Type

Bay Area Startup Rani Therapeutics Tops $70 Million in Funding With Heavy Hitters like AstraZeneca PLC, Novartis AG and Google

BioSpace

Web

Novartis AG Partners With Bay Area's Rani Therapeutics on Revolutionary Robotic Pill

BioSpace

Web

This Alphabet-backed startup wants to turn injectable drugs into pills

Christina Farr

Web

Infobox

Categories

Related Topics

Timeline

March 7, 2018

Venture funding round

On February 7, 2018 Rani Therapeutics completed a venture funding round with $53 million in funding from Shire (lead investor), GeneScience Pharmaceuticals (lead investor), Cathey Venture (lead investor), Bossa Ventures (lead investor), Virtus Inspire Ventures, Ping An Ventures, Google Ventures, and AstraZeneca. 

September 9, 2017

Series D funding round

On September 9, 2017 Rani Therapeutics completed their series D funding round with $39 million in funding from Google Ventures (lead investor), Novartis, and AstraZeneca. 

May 26, 2015

Series C funding round

On May 26, 2015 Rani Therapeutics completed their series C funding round with $37.5 million in funding from Western Life Sciences Venture Fund, VentureHealth, The Stevanato Group, Pinemount Investment, Pacific Venture Opportunity Fund, Novartis, InCube Ventures, Google Ventures, and Crystal Horizon Investments. 

July 28, 2013

Series B funding round

On July 28, 2013 Rani Therapeutics completed their series B funding round with $9.4 million in funding from Google Ventures (lead investor) and InCube Ventures. 

June 13, 2012

Series A funding round

On June 13, 2012 Rani Therapeutics completed their series A funding round with $4 million in funding from InCube Ventures. 

2012

Founding of Rani Therapeutics

Rani Therapeutics is biotherapeutics company based in San Jose, California and was founded in 2012 by Mir Imran.

Edits on 21 Jan 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 Jan 2019 10:10 pm
Edits made to:
Infobox (+1/-1 properties)

Infobox

Edits on 10 Jan 2019
Golden AI
Golden AI edited on 10 Jan 2019 9:45 am
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 9 Jan 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 9 Jan 2019 8:49 pm
Edits made to:
Article (+9/-9 characters)

Article

Edits on 9 Jan 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 9 Jan 2019 12:30 am
Edits made to:
Article (+5/-5 characters)

Article

  • PCSK9PCSK9 - a treatment for cardiovascular disease that is often used with other therapies like statins to lower low-density lipoprotein cholesterol (LDL-C) for patients with hyperlipidemia.
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 9 Jan 2019 12:30 am
Edits made to:
Article (+11/-11 characters)

Article

Rani Therapeutics is biotherapeutics company based in San Jose, California. It develops novel approaches for the oral delivery of peptides, proteins, and therapeutic antibodies that can normally only be delivered through injections. The approach and technology for Rani Therapeutics was developed at InCube LabsInCube Labs, a multidisciplinary R&D lab focused on developing medical innovations.

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 9 Jan 2019 12:30 am
Edits made to:
Article (+8/-8 characters)

Article

  • Factor VIII, Factor IX, Factor XFactor X - treatments of blood clotting disorders, including Hemophilia A and B.
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 9 Jan 2019 12:30 am
Edits made to:
Article (+15/-15 characters)

Article

  • Ocreotide - lowers levels of excess growth hormonesgrowth hormones for the treatment of acromegaly, a disorder characterized by enlargement of face, hands, and feet.
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 9 Jan 2019 12:30 am
Edits made to:
Article (+20/-20 characters)

Article

Rani Therapeutics is biotherapeutics company based in San Jose, CaliforniaSan Jose, California. It develops novel approaches for the oral delivery of peptides, proteins, and therapeutic antibodies that can normally only be delivered through injections. The approach and technology for Rani Therapeutics was developed at InCube Labs, a multidisciplinary R&D lab focused on developing medical innovations.

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 9 Jan 2019 12:30 am
Edits made to:
Article (+11/-11 characters)

Article

  • Factor VIIIFactor VIII, Factor IX, Factor X - treatments of blood clotting disorders, including Hemophilia A and B.
Edits on 6 Jan 2019
Sameeha Sulaiman
Sameeha Sulaiman edited on 6 Jan 2019 8:36 pm
Edits made to:
Infobox (+2/-2 properties)
Article (+2201 characters)
People (+9 rows) (+18 cells) (+325 characters)
Further reading (+1 rows) (+4 cells) (+378 characters)

Article

Rani Therapeutics is biotherapeutics company based in San Jose, California. It develops novel approaches for the oral delivery of peptides, proteins, and therapeutic antibodies that can normally only be delivered through injections. The approach and technology for Rani Therapeutics was developed at InCube Labs, a multidisciplinary R&D lab focused on developing medical innovations.



It's main product, Rani's 'robotic' pill is a device which navigates through the stomach and enters the small intestine. The capsule then goes through a transformation and aligns itself and injects the drug into the intestinal wall. Rani has identified several potential molecules to be used with the RaniPill:

  • Ocreotide - lowers levels of excess growth hormones for the treatment of acromegaly, a disorder characterized by enlargement of face, hands, and feet.
  • Basal Insulin - used in diabetes management as a way to regulate glucose levels in between meals.
  • GLP-1 - a class of drugs used in the treatment of Type II diabetes and obesity.
  • Parathyroid Hormone (PTH) - commonly used for the treatment of osteoporosis, PTH increases the concentration of calcium in the blood by acting upon the parathyroid hormone 1 & 2 receptor.
  • Human Growth Hormone (HGH) - a peptide hormone that stimulates growth, cell reproduction, and regeneration, and is used in the treatment of growth disorders and growth deficiency.
  • Human Interferon beta-1a - a cytokine or small protein in the interferon family used for the treatment of multiple sclerosis.
  • TNF-alpha (TNFa) Inhibitors - supresses response to tumor necrosis factor, part of the inflammatory response. Used to treat a number of inflammatory disorders including rheumatoid arthritis and Crohn's disease.
  • Interleukin Antibodies - various antibodies targeting specific interleukins for the treatment of various inflammatory diseases, such as rheumatoid arthritis, Chrohn's disease, and psoriasis.
  • PCSK9 - a treatment for cardiovascular disease that is often used with other therapies like statins to lower low-density lipoprotein cholesterol (LDL-C) for patients with hyperlipidemia.
  • Factor VIII, Factor IX, Factor X - treatments of blood clotting disorders, including Hemophilia A and B.

People

Name
Role
Related Golden topics

Angela Murch

Vice President



Arvinder Dhalla

Senior Director of Strategy & Program Management



Betsy Gutierrez

Associate VP of Quality Assurance



Dr. Rudi Ruffy

Medical Director



Mir Hashim

Chief Scientific Officer



Mir Imran

Chairman & CEO



Stephanie McGrory

VP of Business Development



Svai Sanford

CFO



Wilfredo Ortiz

Associate VP of Manufacturing



Further reading

Title
Author
Link
Type

Shire and Rani Therapeutics Enter into Collaboration to Evaluate Use of the Rani Pill(TM) Technology for the Oral Delivery of Factor Therapy

Shire Pharmaceuticals Group

Web

Infobox